We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

47 hedge funds and large institutions have $14.1M invested in Titan Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

18,367% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $6K

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

0% more funds holding

Funds holding: 47 → 47 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

17% less capital invested

Capital invested by funds: $17M → $14.1M (-$2.9M)

Holders
47
Holders Change
–
Holders Change %
0%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
11
Reduced
4
Closed
8
Calls
$1.11M
Puts
$6K
Net Calls
+$1.1M
Net Calls Change
+$45K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$724K
2
Renaissance Technologies
Renaissance Technologies
New York
+$690K
3
BFA
BlackRock Fund Advisors
California
+$404K
4
SO
STRS Ohio
Ohio
+$370K
5
GCP
GSA Capital Partners
United Kingdom
+$303K

Top Sellers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
-$305K
2
Millennium Management
Millennium Management
New York
-$146K
3
SIM
Spark Investment Management
New York
-$141K
4
State Street
State Street
Massachusetts
-$101K
5
SG Americas Securities
SG Americas Securities
New York
-$96K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$106K – – –
VKH
27
Virtu KCG Holdings
New York
$95K -$84.2K -5 -42%
RHBC
28
R.H. Bluestein & Co
Michigan
$80K – – –
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$78K – – –
Citigroup
30
Citigroup
New York
$76K – – –
Deutsche Bank
31
Deutsche Bank
Germany
$75K +$67.3K +4 +400%
TDC
32
Thompson Davis & Co
Virginia
$65K – – –
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$60K – – –
ARTA
34
A.R.T. Advisors
New York
$58K +$67.3K +4 New
PPA
35
Parametric Portfolio Associates
Washington
$52K +$16.8K +1 +33%
NFA
36
Nationwide Fund Advisors
Ohio
$48K – – –
NI
37
Numeric Investors
Massachusetts
$48K +$50.5K +3 New
AIG
38
American International Group
New York
$43K – – –
BA
39
BlackRock Advisors
Delaware
$40K – – –
DADC
40
D.A. Davidson & Co
Montana
$40K – – –
Wells Fargo
41
Wells Fargo
California
$40K – – –
BGIM
42
Brandywine Global Investment Management
Pennsylvania
$39K +$50.5K +3 New
UBS Group
43
UBS Group
Switzerland
$13K – – –
BCM
44
Blume Capital Management
California
$10K – – –
Simplex Trading
45
Simplex Trading
Illinois
$8K +$16.8K +1 New
WIM
46
Westside Investment Management
California
$7.72K +$16.8K +1 New
AIM
47
Arcadia Investment Management
Michigan
$7K – – –
LTFS
48
Ladenburg Thalmann Financial Services
Florida
$6K – – –
Legal & General Group
49
Legal & General Group
United Kingdom
$6K – – –
MFS
50
MSI Financial Services
Massachusetts
$6K – – –
1
2
3

TTNP Hedge Fund Activity: Q4 2016 in Review

47 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2016, worth a combined $14.1M — down 17% from $17M a quarter earlier.

Fund positioning in TTNP was balanced in Q4 2016: 8 funds opened new positions, 8 closed out, 11 added to existing stakes and 4 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $724K. The largest seller was AQR Capital Management, exiting entirely with an estimated $305K sold.

  • 47 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $14.1M of Titan Pharmaceuticals stock for Q4 2016, down 17% quarter-over-quarter.
  • 8 funds opened new Titan Pharmaceuticals positions in Q4 2016 and 8 closed out, a net change of 0 holders.
  • The largest Titan Pharmaceuticals buyer in Q4 2016 was Morgan Stanley, an estimated $724K added.
  • The largest Titan Pharmaceuticals seller in Q4 2016 was AQR Capital Management, an estimated $305K sold.

Based on aggregated 13F filings for Q4 2016.